...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Clinical use of sibutramine.
【24h】

Clinical use of sibutramine.

机译：西布曲明的临床用途。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Since obesity is a chronic disorder, a long-term approach is essential, and modern obesity pharmacotherapy means medicating as an adjunct to diet and physical activity not only to achieve weight loss, but also to maintain it. Sibutramine is a US Food and Drug Administration- and European Committee for Proprietary Medicinal Products-approved medication with demonstrated efficacy in long-term obesity management. It is a norepinephrine-serotonin reuptake inhibitor and produces weight loss by a dual mechanism: reduction of food intake and increase in energy expenditure. Sibutramine is given once daily in doses ranging from 5-15 mg. The amount of weight lost with sibutramine is related to both the dose of the drug and the intensity of the behavioral therapy component. Sibutramine produces a weight loss from baseline of more than 5% in over 75% of patients who are prescribed 15 mg daily, and it produces weight loss that averages 5-8% from baseline, independently of the behavioral approach. Weight loss with sibutramine is associated with improvement in waist circumference, lipids, glycemic control, uric acid and health-related quality of life. Sibutramine use is associated with small increases in mean resting blood pressure, but the individual response is variable and not all patients will have blood pressure increases. The drug is also associated with small increases in mean heart rate and should therefore not be used in patients with a history of cardiac arrhythmia. Because it is a serotonin and norepinephrine reuptake inhibitor, sibutramine should not be used with monoamine oxidase inhibitors or noradrenergic agents, and caution is advised in prescribing sibutramine to patients on selective serotonin reuptake inhibitor antidepressants. Given the growing appreciation for the health benefits that can be achieved with even a relatively small weight loss, physicians must become adept in office approaches to achieve modest weight loss. Sibutramine is a useful adjunct to diet and physical activity approaches and can help selected patients achieve and maintain weight loss with concomitant health benefits.
机译：由于肥胖症是一种慢性疾病，因此长期治疗是必不可少的，现代肥胖症药物治疗意味着将药物作为饮食和体育锻炼的辅助手段，不仅可以减轻体重，而且可以维持体重。西布曲明是美国食品药品监督管理局和欧洲专用药品委员会批准的药物，在长期肥胖管理中具有证明的疗效。它是去甲肾上腺素5-羟色胺再摄取抑制剂，并通过双重机理引起体重减轻：食物摄入减少和能量消耗增加。西布曲明每天给药一次，剂量范围为5-15毫克。西布曲明引起的体重减轻量与药物剂量和行为治疗成分的强度有关。西布曲明在每天处方15 mg的超过75％的患者中，从基线产生的体重减轻超过5％，并且与行为方法无关，从基线产生的体重减轻平均为5-8％。西布曲明使体重减轻与腰围，脂质，血糖控制，尿酸和健康相关的生活质量改善有关。西布曲明的使用与平均静息血压的小幅升高有关，但是个体反应是可变的，并非所有患者都会使血压升高。该药物还与平均心率小幅增加有关，因此，不应在有心律不齐史的患者中使用。因为是5-羟色胺和去甲肾上腺素再摄取抑制剂，所以西布曲明不宜与单胺氧化酶抑制剂或去甲肾上腺素能药物一起使用，建议在选择西伯曲明处方时应谨慎使用选择性5-羟色胺再摄取抑制剂抗抑郁药的患者。鉴于人们对即使通过相对较小的体重减轻就可以获得的健康益处日益赞赏，医生必须精通办公室方法以实现适度的体重减轻。西布曲明是饮食和体育锻炼方法的有用辅助手段，可帮助选定的患者实现并保持体重减轻，并带来健康益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号